Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Beijing Ningmei Haowei Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Beijing Ningmei Haowei Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beijing Ningmei Haowei Biotechnology
Developer of a gene editing cell therapy platform designed to advance precision treatments for aging and metabolic conditions. The company offers innovative manufacturing pipelines, targeted chronic disease protocols, and clinical application support, enabling healthcare providers and researchers to deliver personalized regenerative interventions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Ownership
- Privately Held (backing)
Beijing Ningmei Haowei Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beijing Ningmei Haowei Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beijing Ningmei Haowei Biotechnology in its N-PORT filings yet. We sweep new filings monthly.